This text is provided for reference. The official version is published by the Turkish Medicines and Medical Devices Agency (TİTCK).
Section I – Introduction and Scope
1.1. Introduction and scope
This Module was prepared to provide guidance on how communication and coordination of information on medicine safety should be carried out. Communicating safety information to patients and healthcare professionals is a public health responsibility and is essential for pharmacovigilance to achieve its objectives of promoting the rational, safe and effective use of medicines, preventing harm from adverse reactions, minimising risks and contributing to the protection of patients' and public health.
Communicating information on medicine safety is a very broad term that covers different types of information on medicines, including the statutory information that the product information must contain (the summary of product characteristics (SmPC), the patient information leaflet (PL) and the labelling). Although some of the principles in this Module (sections 2.1 and 2.2) apply to all types of safety communication, the Module as a whole focuses on "important new safety information", i.e. new information about a previously known or unknown risk of a medicine that has or may have an impact on its benefit-risk balance and conditions of use. Unless stated otherwise, "communication of safety information" in this Module should be understood as referring to new safety information.
When new safety concerns arise, a high level of public interest is to be expected, and it is important that messages are delivered in a timely, clear and consistent manner. While the second section of this Module defines the principles and tools of safety communication, it gives particular attention to direct healthcare professional communications (DHPCs) and guidance on how to prepare them. This is because the preparation of DHPCs requires marketing authorisation holders and the Agency to act in a coordinated way.
Section II – Structures and processes
2.1. Objectives
The main objectives of communicating medicine safety information to healthcare professionals or the public are:
- To provide timely, evidence-based information on the safe and effective use of medicines,
- To facilitate changes in healthcare practice where necessary,
- To change attitudes, decisions and behaviours in relation to the use of medicines,
- To support risk minimisation behaviour,
- To facilitate informed decisions on the rational use of medicines.
2.2. Key principles
The key principles to consider when communicating medicine safety information to healthcare professionals or the public are:
- Delivering fit-for-purpose, clear, accurate and consistent messages, and getting the information to the target audience at the right time so that appropriate action can be taken,
- Using language suited to the target audience (e.g. patients or healthcare professionals), taking into account different levels of knowledge and information needs while maintaining the accuracy and consistency of the information conveyed,
- Assessing the need for communication throughout the pharmacovigilance and risk management process, as part of risk assessment and risk minimisation,
- Ensuring adequate coordination and cooperation between the different parties involved in the dissemination process (e.g. the Agency and marketing authorisation holders),
- Presenting information on risks in the context of the benefits of the medicine, including available and relevant information on the seriousness, severity, frequency, risk factors, time to onset, reversibility and time to recovery of adverse reactions,
- Addressing uncertainties relating to the safety concern,
- Where appropriate, providing information on competing risks, such as the risk of non-treatment,
- Using the most appropriate quantitative measures when describing and comparing risks (e.g. stating absolute risk and not only relative risk) and, when comparing risks, using denominators of the same magnitude (other tools such as graphics may also be used to present risks and/or the benefit-risk balance),
- Where possible, consulting patients and healthcare professionals and pre-testing the message when preparing a safety communication, especially for complex safety concerns,
- Issuing a follow-up communication when more information on the safety concern becomes available (such as resolution of the safety concern or updated recommendations),
- Where possible, evaluating the effectiveness of the safety communication (see 2.6),
- Complying with personal data protection and confidentiality requirements.
2.3. Target audiences
The primary target audiences of medicine safety communications issued by the Agency and marketing authorisation holders are healthcare professionals, patients and their carers.
Healthcare professionals play a key role in ensuring the effective and safe use of medicines. Safety communications support patient safety by giving healthcare professionals clear and useful information that they can pass on to patients, and help increase trust in the regulatory system. Appropriate information on any safety issue should reach healthcare professionals at the same time, whether they are in practice or involved in clinical trials.
Patient, consumer and healthcare professional organisations can play an additional role in disseminating important safety information to the target audience.
The media are also among the target audiences of safety communications. The media's ability to reach patients, healthcare professionals and the public plays a critical role in communicating new and important information on medicines more widely. The way safety information is conveyed through the media will influence public perception. It is therefore important that safety information is also communicated to the media directly by the Agency, in addition to what they receive from other sources such as marketing authorisation holders.
2.4. Content of a safety communication
The information in a safety communication must not be misleading and must be presented objectively [Regulation on the Safety of Medicinal Products, Article 22(12)]. A safety communication must not contain any statement or material promoting the medicine.
Taking into account the key principles in 2.2, a safety communication should include:
- Important new information that has an impact on the benefit-risk balance of medicines under any condition of use,
- A clear explanation to the target audience of why the safety communication is needed,
- Recommendations to healthcare professionals and patients on how to deal with the safety concern,
- A statement of the agreement reached between the marketing authorisation holder and the Agency on the safety information communicated (where applicable),
- Information on proposed changes to the product information (e.g. SmPC or PL),
- Any additional information on the use of the medicine or other data to tailor the message to the target audience,
- Where relevant, a list of literature references or a reference to sources where more detailed information can be obtained,
- Where necessary, a reminder that suspected adverse reactions should be reported to the Turkish Pharmacovigilance Centre (TÜFAM).
2.5. Tools used to communicate safety issues
Communication tools and channels have multiplied and diversified over time, making it possible to provide more information to the public than ever before. To reach target audiences and meet their growing expectations, efforts should be made to use this increasingly diverse range of tools when communicating on medicine safety. The different types of communication tools and channels are discussed in sections 2.5.1 to 2.5.10.
2.5.1. Direct Healthcare Professional Communications (DHPC) (healthcare professional information letters)
Direct healthcare professional communications are letters delivered directly to healthcare professionals by the marketing authorisation holder or the Agency containing important safety information intended to ensure the safe and effective use of medicines. A DHPC must not contain any material or statement that could be considered promotional, nor give the impression of having a commercial purpose. Direct communication with healthcare professionals concerning quality defects of medicines is outside the scope of pharmacovigilance.
DHPCs should not be used to disseminate safety information that does not require urgent communication, or information that it is not important to convey to healthcare professionals individually, such as SmPC changes that do not affect the appropriate conditions of use of the medicine.
The marketing authorisation holder and the Agency cooperate in preparing the DHPC text. Agreement between these parties must be reached before the marketing authorisation holder issues a DHPC. This agreement covers both the content of the information (see 2.4) and the communication plan, including the intended recipients and the timetable for issuing the DHPC. When drafting a DHPC, the relevant template (see Annex I and Annex II) and the guidance in the notes within the template must be followed.
Where the active substance concerned has more than one marketing authorisation holder and/or the issue concerns a particular class of medicines, a single consistent message should be given.
Where possible and appropriate, involving the relevant healthcare professional organisations in preparing the DHPC text may be considered, to make sure that the information provided is useful and suited to the target audience.
In line with the principle of consistent information, other communication tools and channels complementing the DHPC may also be used.
A DHPC may serve as an additional risk minimisation activity within a risk management plan (see GVP Module VI).
Situations in which issuing a DHPC should be considered include:
- Suspension or revocation of a marketing authorisation for safety reasons,
- An important change in the use of the medicine due to a restriction of the indication, a new contraindication or a change in the recommended dose for safety reasons,
- Inclusion of important new warnings or precautions for use in the product information,
- New data identifying a previously unknown risk or a change in the frequency or severity of a known risk,
- Substantiated information that the medicine is not as effective as previously thought,
- New recommendations for preventing or treating adverse reactions to a medicine, or for avoiding misuse or medication errors,
- Ongoing assessment of an important potential risk for which the data available at a given time are not yet sufficient to initiate regulatory action (in this case the DHPC should encourage close monitoring of the safety issue in clinical practice and reporting of the adverse reaction, and possibly provide information on how to minimise the potential risk). The Agency may issue a DHPC, or ask the marketing authorisation holder to issue one, whenever it considers this necessary for the medicine to continue to be used safely and effectively.
The proposed date and time of distribution should be planned carefully; ideally a DHPC is distributed at the beginning of the week, but the distribution of urgent information should not be delayed for this reason alone (detailed information on letter distribution is given in Annex I and Annex II). Where a health authority outside Türkiye requires a DHPC to be issued in its country for a medicine that is also authorised in Türkiye, the marketing authorisation holder should inform the Agency. This forms part of the legal requirement for marketing authorisation holders to notify competent authorities of new information that may affect the benefit-risk balance of a medicine.
2.5.2. Communication materials issued by the Agency for healthcare professionals
The Agency may issue medicine safety communications aimed directly at healthcare professionals. These are usually published on the Agency's website. They contain the Agency's recommendations to healthcare professionals for minimising the risk and provide relevant background information.
Taking the public interest into account, the Agency issues safety communications in line with the key principles described above (see 2.2) when there is a need for urgent action or to change current practice in relation to a medicinal product.
The Agency should use the most appropriate tools and channels described in this section to maximise the dissemination and accessibility of the relevant information.
2.5.3. Information in lay language
Communication materials in lay language (e.g. in question-and-answer format) help patients and the public understand the scientific evidence and the regulatory measures taken on a safety issue. Lay-language documents should contain the Agency's recommendations and advice to patients and physicians for minimising the risk related to the safety issue, as well as relevant background information.
Lay-language documents are generally useful for members of the public who are interested in the topic but have no training in scientific or regulatory matters. These documents should refer to other communication materials where the reader can find more detailed information.
Lay-language documents are published on the Agency's official web portals and may additionally be distributed to relevant parties such as patient and healthcare professional organisations.
Where possible, involving patients and healthcare professionals in preparing lay-language documents is recommended, to make sure the information provided is understood by, and useful to, the target audience.
2.5.4. Press communication
Press communication mainly comprises press releases and press briefings prepared for journalists.
In addition to publishing press releases on its official website, the Agency may send them directly to journalists. This ensures that, in addition to information from other sources, journalists receive information consistent with the authority's scientific assessment. Interaction with the media is one of the main ways of reaching wider audiences and increasing trust in the regulatory system.
Press releases may also be prepared and issued by marketing authorisation holders. However, when information on pharmacovigilance concerns relating to the use of medicines is to be made public, the Agency must be informed beforehand or at the same time. The marketing authorisation holder guarantees that this information is accurate and not misleading. Press releases by marketing authorisation holders should refer to any regulatory measures the Agency may have initiated and to related ongoing reviews.
Although prepared for journalists, press releases will also be read by other audiences such as healthcare professionals, patients and the public. Reference should therefore be made to the relevant communication materials on the topic. Where a DHPC has also been prepared, it should preferably be shared with healthcare professionals before the press release is published, so that they are better prepared to answer patients.
A short briefing with journalists by the Agency may be considered when safety concerns or other medicine safety topics attract high media interest, or when complex or public-health-sensitive messages need to be communicated.
2.5.5. Websites
Websites are a key tool for patients and healthcare professionals who actively search the internet for specific information on medicines. The Agency and marketing authorisation holders should ensure that important safety information published on websites under their control is easily accessible and understandable to the public. Information on websites should be kept up to date and outdated information removed.
2.5.6. Social media and other online communication tools
Online safety information may also be disseminated through social media and other internet tools. When newer, faster communication channels are used, particular care should be taken not to compromise the accuracy of the information published.
2.5.7. Bulletins and newsletters
Medicine safety bulletins provide new information on the safety and effectiveness of medicines at regular intervals and reach wide audiences. Bulletins also make it possible to remind readers collectively of medicine safety topics that have previously been communicated in various ways.
The Agency can reach a wide audience with these tools using web-based and other available means.
2.5.8. Communication between authorities
When taking its own decisions on a specific safety concern, or taking new regulatory action, the Agency may also take into account assessments made by other health authorities with comparable standards or by regional or international organisations, and may share information on request.
2.5.9. Responding to requests for information from the public
The Agency and marketing authorisation holders should have mechanisms in place to answer questions about medicines from individual members of the public. Answers should take publicly available information into account and be based on the product information approved by the Agency. Where questions concern individual treatment advice, the patient should be advised to consult a healthcare professional. In this respect, marketing authorisation holders are subject to the provisions of the Regulation on Promotional Activities for Medicinal Products for Human Use.
2.5.10. Other communication tools
In addition to those discussed above, other tools and channels exist, such as scientific journal publications and the journals of professional bodies.
Some tools and channels may be used in the context of risk management. In addition to the product information, other communication tools may be used to disseminate product information. These are considered additional risk minimisation measures and may include patient alert cards or educational materials. They are, however, outside the scope of this Module and are described in detail in GVP Module VI.
2.6. Effectiveness of safety communication
A safety communication is considered effective when the message is received and understood by the target audience as intended and appropriate action is taken by that audience. Where possible, mechanisms should be put in place to measure the effectiveness of the communication. A research-based approach is appropriate to show that safety communications meet the standard set in 2.2. Such an approach can measure different outcomes, including behaviour, attitudes and knowledge. When evaluating the effectiveness of safety communication, the scope may be widened to include factors other than the performance of the individual communication tools. Correct implementation of the steps of the risk communication plan is critical to the effectiveness of safety communication (see Annex III). For DHPCs, the marketing authorisation holder is responsible for evaluating the distribution of the DHPC it prepared and should report the outcome and any difficulties identified (e.g. problems with the recipient list, timing or distribution mechanism) to the Agency. Measures should be taken to correct the situation or prevent similar problems in the future.
2.7. Quality system requirements for safety communication
In line with the quality system requirements in GVP Module IV – Pharmacovigilance Quality System, procedures should be in place to ensure that safety communications comply with the principles set out in 2.2.
Communications should be subject to quality control, in particular to ensure their accuracy and clarity. To this end, review procedures with defined responsibilities should be followed and documented.
Section III – Implementation of safety communication
3.1. Coordination of safety communication
The Agency informs healthcare professionals about medicine safety topics through its official website. The medicine safety announcements made on the Agency's website and the responsible departments are listed in the table below.
| Topic | Responsible department |
|---|---|
| Current announcements / Important announcements | All departments |
| Physician information letters (DHPC) | Department of Pharmacovigilance and Controlled Substances |
| List of medicines subject to additional monitoring | Department of Pharmacovigilance and Controlled Substances |
| List of medicines used with Drug Safety Monitoring Forms | Department of Pharmacovigilance and Controlled Substances |
| Risk management materials | Department of Pharmacovigilance and Controlled Substances |
| Announcements from unions, associations and companies | Department of Marketing Authorisation; Department of Pharmacovigilance and Controlled Substances |
| SmPC/PL | Department of Marketing Authorisation |
| Batch blocking and recall announcements | Department of Inspection |
Annex I – DHPC template
<Date>
<Active substance, name of the medicine and main message (e.g. information on a warning or contraindication)> Note: if the medicine is subject to additional monitoring, the inverted black equilateral triangle should be added to the title before the medicine name or active substance. The additional monitoring statement should be added at the end of the letter.
Dear Healthcare Professional, The purpose of this letter is to inform you about ……….. This letter has been prepared in agreement with the Ministry of Health, Turkish Medicines and Medical Devices Agency, Department of Pharmacovigilance and Controlled Substances. This letter is also available at www.titck.gov.tr.
Summary
Explanation: the font in this section should be larger than in the other sections of the DHPC or in bold, and bullet points should preferably be used.
- <Short description of the safety issue in the context of the therapeutic indication, recommendations for minimising the risk (e.g. contraindications, special warnings and precautions for use) and, where applicable, switching to an alternative treatment>
- <Where applicable, recall information (e.g. pharmacy or patient level) and date of recall>
Further information on the safety concern and the recommendations
Explanation: this section may include the following information: <Short description of the therapeutic indication of the medicine> <Important details of the safety issue, including the reason for distributing the DHPC (adverse reaction, seriousness, statement on suspected causal relationship and, if known, pharmacodynamic mechanism, temporal relationship, positive rechallenge or dechallenge, risk factors)> <Estimate of the frequency of the adverse reaction or reporting rates, together with estimated patient exposure> <Where applicable, a statement indicating any relationship between the adverse reaction and off-label use> <Where necessary, details of recommendations on risk minimisation> <If the product information has been or will be changed, a statement including a description of the changes made or proposed> <Assessment of the risk concerned in the context of the benefits of the medicine> <Reason for issuing the DHPC at this time> <Any evidence supporting the recommendation (e.g. references to key study/studies)> <Statement on DHPCs recently distributed on the current safety issue>
<Where applicable, a schedule for follow-up activity(ies) by the marketing authorisation holder / the Agency>
Call for reporting
<Reminder of the need to report adverse reactions to the Turkish Pharmacovigilance Centre (TÜFAM) and/or the company's qualified person for pharmacovigilance, and how to report (e.g. postal address, fax number, official website)> <For biological medicinal products, a reminder to report the product name and batch numbers> <Whether the medicine is subject to additional monitoring>
Company's qualified person for pharmacovigilance
<Details of the pharmacovigilance contacts for further information, relevant website address(es), telephone numbers and postal addresses>
Annexes (where applicable)
<Relevant revised sections of the product information text (with changes visible)> <Detailed scientific information where necessary> <Where possible, a list of literature references>
Annex II – DHPC distribution scheme
Identifying the need for a letter
The issue concerns more than one product
The issue concerns a single product
Letter prepared on the marketing authorisation holder's letterhead, signed by the holder's qualified person for pharmacovigilance and one superior, and distributed
Letter prepared on the Agency's letterhead
Distribution by the marketing authorisation holder designated by the Agency
- The letter is distributed to physicians prescribing the medicines, hospital chief physicians, relevant specialist societies, and the deans of university faculties of pharmacy and medicine.
- Distribution may be by courier, medical representative or e-mail (courier or e-mail is preferred in a pandemic).
- A closing report on the distribution of the letter is submitted to the Department of Pharmacovigilance and Controlled Substances within 15 working days.
- The closing report gives an overall assessment of the distribution (distribution route and, if any, the websites on which it was announced), information on when distribution started and how many days it took to complete, delivery statistics (such as the delivery percentage, the size of the target audience and the percentage of recipients who could not be reached) and any problems encountered. If distribution is by e-mail, e-mail receipt and read information from the sending reports is added to the closing report.
Preparation of the closing report and its submission to the Agency
Annex III – Risk communication plan
For the risk communication plan diagram, please refer to the PDF published by TİTCK.
Revision history
| Revision No | Revision date | Reason and explanation |
|---|---|---|
| 1 | 15.11.2022 | Format updated |
